Indofarma

AN audit by the Supreme Audit Agency (BPK) finally uncovered the rot within the management of Indofarma, a state-owned company engaged in the production of pharmaceuticals and medical equipment. At the end of 2023, state auditors conducted a special purpose audit (PDTT). During the initial audit, they found irregularities indicating criminal activities, otherwise known as fraud.

The BPK then raised the status of its audit of Indofarma and all it

Subscribe to continue reading.
We craft news with stories.

For the benefits of subscribing to Digital Tempo, See More

The Best Choice

Rp 54.945/Month

Active for 12 Months, Rp 659.340

• *You Save -Rp 102.000
• *Guaranteed update of up to 52 Editions of Tempo Magazine

Subscribe

Rp 64.380/Month

Active Every Month Cancel Anytime

• *Free for the first month if using a Credit Card

Subscribe

See Other Packages

Already a Subscribed? Log in here
To receive daily news by Email, Sign up for Tempo ID.